(Q34165511)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332315%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

review article

1 reference

title

Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332315%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332315%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Markus R Meyer

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332315%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

1 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332315%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332315%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332315%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332315%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

215-233

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332315%20AND%20SRC:MED&resulttype=core&format=json

Pharmacogenetics and human genetic polymorphisms

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Atypical antipsychotic metabolism and excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Pharmacogenomics and individualized drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Can pharmacogenetics help rescue drugs withdrawn from the market?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Enzyme kinetics for clinically relevant CYP inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Pharmacogenomics--drug disposition, drug targets, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Designer drugs that are potent inhibitors of CYP2D6

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Interactions between recreational drugs and antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Summary of information on human CYP enzymes: human P450 metabolism data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Polymorphism of human cytochrome P450 enzymes and its clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Propofol metabolism is enhanced after repetitive ketamine administration in rats: the role of cytochrome P-450 2B induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Genetics of the variable expression of CYP3A in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Influence of dietary components on the gastrointestinal metabolism and transport of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Pharmacogenetics of phase I and phase II drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Glutathione S-transferase polymorphisms and their biological consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Metabolism of designer drugs of abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Metabolism of designer drugs of abuse: an updated review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Detection time of drugs of abuse in urine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Detection times of drugs of abuse in blood, urine, and oral fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Personalized therapy in pain management: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

The burden of the nonmedical use of prescription opioid analgesics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Accelerated nonmuscle contraction after subarachnoid hemorrhage: culture and characterization of myofibroblasts from human cerebral arteries in vasospasm.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Urinary metabolites of DL-methadone in maintenance subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Role of CYP2B6 in stereoselective human methadone metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Interindividual variability of methadone response: impact of genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Clinical Investigation of the Analgesic Potency and Respiratory Depressant Activity of Fentanyl, a New Narcotic Analgesic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

An analysis of the duration of fentanyl and its metabolites in urine and saliva.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Pharmacokinetic interactions between buprenorphine and antiretroviral medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Inhibition and active sites of UDP-glucuronosyltransferases 2B7 and 1A1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Morphine-6-glucuronide: actions and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Inhibition of cytochrome P450 2D6 modifies codeine abuse liability

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Codeine intoxication associated with ultrarapid CYP2D6 metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

GHB: a new and novel drug of abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Forensic toxicology findings in deaths involving gamma-hydroxybutyrate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

The gamma-hydroxybutyrate withdrawal syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Enzymes involved in the metabolism of gamma-hydroxybutyrate in SH-SY5Y cells: identification of an iron-dependent alcohol dehydrogenase ADHFe1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

GAMMA-HYDROXYBUTYRATE, A NORMAL BRAIN METABOLITE.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Gamma-hydroxybutyrate--a drug of abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Conversion of gamma-hydroxybutyrate to gamma-aminobutyrate in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

TPN-L-gluonate dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Evidence for a role of high Km aldehyde reductase in the degradation of endogenous gamma-hydroxybutyrate from rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Kinetic characterization of human hydroxyacid-oxoacid transhydrogenase: relevance to D-2-hydroxyglutaric and gamma-hydroxybutyric acidurias

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

An overview of ?-hydroxybutyrate catabolism: The role of the cytosolic NADP+-dependent oxidoreductase EC 1.1.1.19 and of a mitochondrial hydroxyacid-oxoacid transhydrogenase in the initial, rate-limiting step in this pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

4-Hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn error of GABA metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Gamma-hydroxybutyrate in urine and serum: additional data supporting current cut-off recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

The abuse potential of propofol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Species differences in blood profiles, metabolism and excretion of14C-propofol after intravenous dosing to rat, dog and rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Use of proton nmr spectroscopy to measure propofol metabolites in the urine of the female Caucasian patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Involvement of human liver cytochrome P4502B6 in the metabolism of propofol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Propofol metabolites in man following propofol induction and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Ketamine: its mechanism(s) of action and unusual clinical uses.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Non-medical use of ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Breaking the drug addiction cycle is not easy in ketamine abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Urinary excretion rates of ketamine and norketamine following therapeutic ketamine administration: method and detection window considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

GC-MS quantification of ketamine, norketamine, and dehydronorketamine in urine specimens and comparative study using ELISA as the preliminary test methodology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Metabolism and toxicological detection of a new designer drug, N-(1-phenylcyclohexyl)propanamine, in rat urine using gas chromatography-mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Metabolism and toxicological detection of the designer drug N-(1-phenylcyclohexyl)-3-methoxypropanamine (PCMPA) in rat urine using gas chromatography-mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

New designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-3-ethoxypropanamine and N-(1-phenylcyclohexyl)-3-methoxypropanamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Professor's little helper

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Predictors of nonmedical ADHD medication use by college students

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Prevalence of ADHD diagnosis and nonmedical prescription stimulant use in medical students.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Detection of modafinil in human urine by gas chromatography-mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Chiral analysis of d- and l-modafinil in human serum: application to human pharmacokinetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

The pharmacology of lysergic acid diethylamide: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Indolealkylamines: biotransformations and potential drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Pattern of use and subjective effects of Salvia divinorum among recreational users.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

The pharmacology of psilocybin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Detection of psilocin in body fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Metabolism and disposition kinetics of nicotine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Nicotine chemistry, metabolism, kinetics and biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Human CYP2A6 is induced by estrogen via estrogen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

Poll results: look who's doping

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.171

21 January 2018

Identifiers

DOI

10.2217/PGS.10.171

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332315%20AND%20SRC:MED&resulttype=core&format=json

release_f6raozhyr5hxbkcx6ztulydome

22 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/f6raozhyr5hxbkcx6ztulydome

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference